Inhibikase Therapeutics (IKT) Cash from Operations (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash from Operations data on file, last reported at 12059722.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 193.89% year-over-year to 12059722.0 in Q1 2026; TTM through Mar 2026 was 35742656.0, a 84.39% decrease from a year earlier, with the FY2025 full-year figure at 27786464.0, down 45.11% from the prior year.
• Cash from Operations for Q1 2026 stood at 12059722.0, down from 7515973.0 in the prior quarter.
• Over the last five years, Cash from Operations for IKT reached as high as 3442431.0 in Q4 2023 and fell as low as 12059722.0 in Q1 2026.
• Historically, Cash from Operations has averaged 5554729.35 across 5 years, with a median of 4881100.0 in 2024.
• Across the five-year window, Cash from Operations surged 35.25% in 2024 and slumped 193.89% in 2026, its largest moves.
• Year by year, Cash from Operations stood at 3556374.0 in 2022, then rose by 3.2% to 3442431.0 in 2023, then plunged by 55.28% to 5345575.0 in 2024, then slumped by 40.6% to 7515973.0 in 2025, then tumbled by 60.45% to 12059722.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 12059722.0 in Q1 2026, 7515973.0 in Q4 2025, and 10592730.0 in Q3 2025.